Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy and safety of oral BAY63-2521 in patients with chronic thromboembolic pulmonary hypertension (CTEPH) has completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension
• Thromboembolic Pulmonary Hypertension

Drugs mentioned

• BAY63-2521

Snippet

Sponsor: Bayer | Conditions: Pulmonary Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2014-03-11